APOE and Alzheimer disease: Utilizing apoE molecules whose N- and C-terminals were fluorescently labeled coupled with a high throughput screening approach, small druggable molecules that inhibit apoE4 domain interactions and counteract the key pathological effects of apoE4 in vitro were identified [195], thus providing a proof-of-principle that correcting the pathogenic conformation of apoE4 is a viable therapeutic approach for apoE-related processes in AD.